AtaiBeckley's BPL-003 Shows Strong Phase 2a Results in TRD Patients on SSRIs; Phase 3 On Track
ATAI has more than doubled off its 52-week low of $1.15.
Summary
This news reports positive Phase 2a results for AtaiBeckley's BPL-003, demonstrating rapid and durable antidepressant responses in treatment-resistant depression (TRD) patients who remained on stable SSRI therapy. A 66.7% response rate was observed at Day 2, with 83% and 66.7% maintaining response at Week 12 in the 10 mg and 12 mg cohorts, respectively. The drug was well-tolerated, and patients were ready for discharge in approximately 100 minutes post-dose, highlighting its convenience. This is a significant development as it shows efficacy in a difficult-to-treat population while allowing concomitant SSRI use, which is crucial for many TRD patients. The company also confirmed that Phase 3 studies are on track to initiate in Q2 2026 following recent FDA End-of-Phase 2 alignment, building on its existing FDA Breakthrough Therapy Designation. This positive clinical data significantly de-risks the BPL-003 program and provides a strong catalyst for the stock.
At the time of this announcement, ATAI was trading at $4.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $1.15 to $6.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.